BC
Boxer Capital Portfolio holdings
AUM
$2.04B
1-Year Return
108.35%
This Quarter Return
+26.13%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$2.02B
AUM Growth
+$18.4M
(+0.92%)
Cap. Flow
-$112M
Cap. Flow
% of AUM
-5.51%
Top 10 Holdings %
Top 10 Hldgs %
53.81%
Holding
65
New
13
Increased
7
Reduced
4
Closed
6
Top Buys
| 1 |
Fate Therapeutics
FATE
|
+$56.6M |
| 2 |
Nkarta
NKTX
|
+$45M |
| 3 |
Viking Therapeutics
VKTX
|
+$24.6M |
| 4 |
Kura Oncology
KURA
|
+$21.3M |
| 5 |
Allogene Therapeutics
ALLO
|
+$17.2M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$188M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
+$87.8M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$79.1M |
| 4 |
argenx
ARGX
|
+$23.6M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$9.63M |
Sector Composition
| 1 | Healthcare | 99.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $168M | 8.32% |
3,421,541
| – | – |
|
2
Cytokinetics
CYTK
$6.12B
| $147M | 7.27% |
2,100,000
| – | – |
|
3
Revolution Medicines
RVMD
$8.7B
| $138M | 6.81% |
4,279,464
| – | – |
|
4
Tyra Biosciences
TYRA
$667M
| $106M | 5.22% |
6,448,359
| – | – |
|
5
Apellis Pharmaceuticals
APLS
$3.14B
| $101M | 5.01% |
1,726,000
| – | – |
|
6
IDEAYA Biosciences
IDYA
$2.16B
| $96.7M | 4.77% |
2,202,812
| – | – |
|
7
Merus
MRUS
$5.26B
| $85.6M | 4.23% |
1,900,000
| – | – |
|
8
Sarepta Therapeutics
SRPT
$1.82B
| $84.1M | 4.16% |
650,000
| – | – |
|
9
Nuvalent
NUVL
$5.8B
| $84.1M | 4.15% |
1,120,192
| – | – |
|
|
ONC
10
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.7B
| $78.2M | 3.86% |
500,000
| – | – |
|
11
Tango Therapeutics
TNGX
$727M
| $65.1M | 3.22% |
8,198,642
| – | – |
|
|
12
Nkarta
NKTX
$140M
| $60.6M | 2.99% |
5,607,350
+4,167,350
| +289% | +$45M |
|
|
13
Fate Therapeutics
FATE
$111M
| $60.3M | 2.98% |
8,215,910
+7,715,910
| +1,543% | +$56.6M |
|
14
Avidity Biosciences
RNA
$5.76B
| $44.1M | 2.18% |
1,727,388
+606,061
| +54% | +$15.5M |
|
15
Akero Therapeutics
AKRO
$3.48B
| $42.4M | 2.09% |
1,676,733
| – | – |
|
16
Rocket Pharmaceuticals
RCKT
$341M
| $39.5M | 1.95% |
1,466,051
| – | – |
|
|
17
argenx
ARGX
$46.3B
| $39.4M | 1.94% |
100,000
-60,000
| -38% | -$23.6M |
|
18
Legend Biotech
LEGN
$6.11B
| $33.7M | 1.66% |
600,000
| – | – |
|
19
Axsome Therapeutics
AXSM
$5.91B
| $31.9M | 1.58% |
400,000
| – | – |
|
20
Arcus Biosciences
RCUS
$1.23B
| $30.2M | 1.49% |
1,602,200
| – | – |
|
21
AnaptysBio
ANAB
$655M
| $29.3M | 1.45% |
1,300,000
| – | – |
|
22
Immunovant
IMVT
$2.82B
| $26.7M | 1.32% |
825,000
-175,000
| -18% | -$5.65M |
|
23
Xenon Pharmaceuticals
XENE
$2.79B
| $25.8M | 1.28% |
600,000
| – | – |
|
24
Arvinas
ARVN
$568M
| $25.1M | 1.24% |
608,614
| – | – |
|
|
ITOS
25
DELISTED
iTeos Therapeutics
ITOS
| $24.6M | 1.22% |
1,804,058
| – | – |
|